On September 30, 2025, bioAffinity Technologies, Inc. (NASDAQ: BIAF) announced that it had priced a new public offering of securities, raising an aggregate gross proceeds of $4.8 million. The offering consists of 1,921,799 shares of common stock (or pre‑funded warrants) at a purchase price of $2.50 per share (or $2.493 per pre‑funded warrant).
The closing of the offering is expected to occur on or about September 30, 2025, with WallachBeth Capital LLC acting as the sole placement agent. The pre‑funded warrants will be immediately exercisable and will expire upon full exercise, providing the company with flexible capital that can be deployed as needed.
This financing extends bioAffinity’s liquidity runway and provides additional capital to support the commercialization of its CyPath Lung diagnostic platform, fund ongoing clinical development, and potentially bridge the company’s current cash shortfall that was projected to last only through August 2025. The new capital infusion is therefore a significant event that directly affects the company’s financial position and future growth prospects.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.